SRX sierra rutile holdings limited
Add to My Watchlist 0.00% ! 17.5¢

Treatment of Primary Liver Cancer: SARAH Study Completes...

  1. filby
    2,092 Posts.
    lightbulb Created with Sketch. 159
    clock Created with Sketch.
    04/03/15
    22:06
    Post #: 14861222
    Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016


    http://www.virtualpressoffice.com/p...eToDisableHistory=Y&menuName=News&sId=&sInfo=

    mce-anchorPARIS, March 4, 2015 /PRNewswire/ -- SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valerie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hopitaux de Paris (AP-HP) and Universite Paris Diderot, Sorbonne Paris Cite, France.
    Last edited by filby: 04/03/15
    SRX Price at posting: $34.92 Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 3  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS First assay results returned from ongoing drilling at Gold Duke Project
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast 025 – Locksley rap video gives Hilltop Hoods run for money
right-arrow Created with Sketch.
NEWS The biggest ASX director trades from the last week
right-arrow Created with Sketch.
AII A critical metal, a broken supply chain, surging demand, and a Western producer ready to deliver
right-arrow Created with Sketch.
NEWS High-grade silver intercepts confirmed at Kempfield Project
right-arrow Created with Sketch.
NEWS ANSTO continuous piloting confirms exceptional rare earth recoveries
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.